Panbela Therapeutics Announces Q3 2024 Financial Results
Panbela Therapeutics, Inc. ( (PBLA) ) has released its Q3 earnings. Here is a breakdown of the information Panbela Therapeutics, Inc. presented ...
News Medical on MSN1d
Spermidine regulates RIPK1 to combat diabetes and vascular damage
Researchers reveal that spermidine-mediated acetylhypusination of RIPK1 suppresses necroptosis and insulin resistance, ...
Seeking Alpha4d
Panbela Therapeutics, Inc. (PBLA) Q3 2024 Earnings Call Transcript
Our lead assets ivospemin, eflornithine, and Flynpovi target the polyamine pathway in ways that could complement ImmunityBio's natural killer cell and killer T cell activation technology. The ...
Nasdaq4d
Panbela Provides Business Update and Reports Q3 2024 Financial Results
By combining Panbela's polyamine metabolic inhibitor platform ... I believe the combination of immunotherapy and metabolic pathway platforms could create powerful synergies in enhancing patient ...